Freedom of Information Act
Article
Freedom of Information Act is a recurring concept in the Astral Codex Ten archive, appearing 3 times across 3 issues between June 23, 2023 and February 07, 2025. The archive places it in contexts such as “The Freedom of Information Act—championed by Nader, and hailed as an unprecedented mechanism for government transparency when it was passed in 1966”; “thanks to the Freedom of Information Act, the public was close to accessing the details”; “a lot of data is only shared via costly and inefficient Freedom of Information Act (FOIA) requests”. It most often appears alongside civil rights movement, Congress, FDA.
Metadata
- Category: Concepts
- Mention count: 3
- Issue count: 3
- First seen: June 23, 2023
- Last seen: February 07, 2025
Appears In
- Your Book Review: Public Citizens
- Your Book Review: Safe Enough?
- 1DaySooner’s Trump II Health Policy Proposals
Related Pages
-
- civil rights movement (2 shared issues)
-
- Congress (2 shared issues)
-
- FDA (2 shared issues)
-
- Watergate (2 shared issues)
-
- 1960 Valdivia earthquake (1 shared issues)
-
- 1965 (1 shared issues)
-
- 1968 Summer Olympics (1 shared issues)
-
- 1DaySooner (1 shared issues)
-
- 2000 election (1 shared issues)
-
- 2023 book review contest (1 shared issues)
-
- ACX (1 shared issues)
-
- AEC (1 shared issues)
External Links
Source Context
Recovered passages from the original issue text. When the raw archive preserved outbound links inside the source passage, they are listed directly under the quote.
Today, business groups dominate agency notice and comment periods, submitting almost ten time as many comments as public interest groups or individual citizens13. Industry submits over 80% of all comments to the EPA. And the Freedom of Information Act—championed by Nader, and hailed as an unprecedented mechanism for government transparency when it was passed in 1966—is today mostly used by businesses for profit-making purposes14. Among the many projects blocked or delayed by lawsuit activism—or the excessive legal review designed to preempt it—are public transit in Hawaii, wind farms on Cape Cod and upstate New York, and NYC congestion pricing, not to mention the millions of new homes around the country we should be building but aren’t.
Including my own—my former startup occasionally used FOIA exactly like this.
By the early 1970s, after the civil rights movement and Vietnam and with Watergate in full swing, the public was becoming jaded with Big People waving away concerns with Big Promises on the basis of little more than self-proclaimed expertise. And thanks to the Freedom of Information Act, the public was close to accessing the details of what industry leaders actually knew. Big People recognized that this would not be an entirely good look.
Improve FDA Transparency: The FDA sits on the world’s biggest repository of clinical data, yet its transparency policies remain conservative compared to other global regulators. This opacity slows research, because a lot of data is only shared via costly and inefficient Freedom of Information Act (FOIA) requests. For example, the European Medical Association makes public Complete Response Letters (CRLs), which detail critical safety and efficacy findings, but the FDA only shares them with the drug developer. An impactful focus for Makary could be addressing the practical and legal challenges that hinder real transparency reform at the FDA. Here’s a very 2025 solution - train an LLM on the agency’s vast repository of clinical data and deploy it as a tool for reviewers and potential automated researcher itself. By automating institutional knowledge, an AI system could significantly reduce regulatory burden by helping FDA staff review submissions, spot issues, predict outcomes, and write responses.